PDF (15.90 MB) - Boehringer Ingelheim Annual Report 2012

PERSPECTIVES FORMEDICAL INNOVATIONBoehringer Ingelheim’s commitment to emerging science as a basisfor new medicines grows ever stronger.We therefore focus on studying human disease, the subsets of eachdisease and establishing target-disease relationships which enableus to ask the right questions.Our aim to help patients by treating diseases in areas of high unmetmedical need both in our current therapeutic area focus and in newemerging disease areas.Our R&D activities include both small molecules and biotherapeutics,thereby allowing us to choose the most appropriate approach foreach therapeutic concept.RESEARCH AREAS[ in focus: six major areas ]THE BOEHRINGER INGELHEIM PIPELINE[ compounds in development, total 94 ]respiratorydiseasescentral nervoussystem diseasescardiometabolicdiseasesimmunologyoncologyinfectiousdiseases17respiratorydiseases9immunology10cns diseases3infectiousdiseases24oncology31cardiometabolicdiseases40 Boehringer Ingelheim annual report 2012